Dogwood Therapeutics (DWTX) vs SCYNEXIS (SCYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SCYNEXIS (SCYX) has outperformed Dogwood Therapeutics (DWTX) over the past year, losing 32.1% versus a loss of 77.9%. Over five years, SCYX leads with a -90.5% price change compared with -98.8% for DWTX. Dogwood Therapeutics is the larger company by market cap ($47.9 million vs $42.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DWTX | SCYX |
|---|---|---|
| Share price | $1.41 | $4.22 |
| Market cap | $47.93M | $41.99M |
| 1-day change | -1.40% | -11.72% |
| YTD return | -66.11% | -16.53% |
| 1-year return | -77.90% | -32.11% |
| 5-year return | -98.80% | -90.53% |
| P/E ratio (TTM) | 0.64 | — |
| EPS (TTM) | $2.20 | $-0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.04 | $9.12 |
| 52-week low | $1.28 | $3.53 |
| Distance from 52-week high | -79.98% | -53.73% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +892.91% | +760.90% |
| Average volume | 63.50K | 279.10K |
| Shares outstanding | 33.99M | 9.95M |
| Employees | 8 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SCYX has outperformed DWTX by 45.8 percentage points over the past year.
About Dogwood Therapeutics
DWTX stock →Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
DWTX vs SCYX FAQ
Which is bigger, Dogwood Therapeutics or SCYNEXIS?
Dogwood Therapeutics (DWTX) is larger, with a market capitalization of $47.93M compared with $41.99M for SCYNEXIS (SCYX).
Which stock has performed better over the past year, DWTX or SCYX?
SCYX returned -32.11% over the past 12 months, compared with -77.90% for DWTX (price return, excluding dividends). Past performance does not predict future results.
Are Dogwood Therapeutics and SCYNEXIS in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.